The Experts in FDA and USDA Regulatory Matters
EAS Consulting Group is a leading provider of regulatory compliance solutions to industries regulated by FDA, USDA, and supporting agencies. Our team of consultants provide expert guidance for all of your regulatory requirements.
Food
Learn More
Dietary Supplements
Learn More
Pharmaceuticals
Learn More
Medical Devices
Learn More
Tobacco
Learn More
Cosmetics
Learn More
Veterinary
Learn More
Cannabis
Learn More
Our Services: Consulting • Submissions • Auditing • Training • Legal Support
Learn With Us
Seminars
Transition from Computer System Validation (CSV) to Computer Software Assurance (CSA)
The life science industries, including pharmaceutical, medical device, biotechnology, biological, and tobacco and tobacco-related products continue to embrace new technology to improve delivery of quality products in compliance with FDA. In addition, we’ve seen a trend toward making use of cloud services, Software-as-a-Service (SaaS) solutions, and other technical innovations such as use of Artificial Intelligence (AI), Machine Learning (ML) and Large Language Models (LLMs), such as ChatGPT that have more recently begun to be used more heavily in life science companies.
Webinars
Animal Food GRAS: Unpacking the Essentials
Presented by Dr. Adam Orr and Tim LombardoJune 17, 2026 | 3:00 PM ETThe U.S. is one of the most promising and expansive markets for innovative animal food ingredients. However, accessing the US requires knowledge about its regulatory requirements. Among the regulatory...
On Demand Webinars
Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: What Industry Needs to Know
When the FDA issues a Form 483 at the conclusion of a drug CGMP inspection, your response becomes a defining regulatory moment. How you address these observations can directly influence outcomes, including the risk of Warning Letters or further enforcement action. In 2026, the FDA released new draft guidance titled “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.” This will include a focused review of that guidance, breaking down key expectations and what they mean for industry.
Latest News
FDA Issues Guidance on Enforcement Priorities for Unauthorized ENDS and Nicotine Pouch Products
FDA Updates Enforcement Priorities for Unauthorized Tobacco Products FDA’s Center for Tobacco Products (CTP) has issued guidance titled “Enforcement Priorities for Certain New Tobacco Products...
FDA Launches One-Day Inspectional Assessments to Expand Regulatory Oversight
FDA Introduces One-Day Inspectional Assessments The U.S. Food and Drug Administration has announced a new initiative called One-Day Inspectional Assessments, designed to expand oversight activities...
FDA Updates Biosimilar Q&A Draft Guidance
FDA has released updated draft guidance on biosimilar development, clarifying how sponsors can use non-U.S.-licensed comparator products to support biosimilarity and what is required during FDA review.
Get the Newsletter
Subscribe to EASeNews and join the nearly 20,000 who receive the monthly EASeNews regulatory newsletter.
Need Regulatory Support?
Start the Conversation Today